Monday, July 21, 2014

Facebook (FB) Within 5% of Its All-Time High

Facebook (FB) was less that 5% from a new 52-week/all-time high earlier today (02014.07.21 at 12:09pm EST). Right FB is at $69.23. 52-week range: $25.72 - $72.59. FB is 169% above its 52-week low.

Friday, July 18, 2014

Google (GOOG) (GOOGL) Reports 2Q'14 Results

Google (GOOG) (GOOGL) reported 2Q'14 results after the market closed on 02014.07.17.

Free cash flow was $2.98 billion.

Capital expenditures were $2.65 billion.

Cash at the end of 2Q'14 was $61.20 billion.

"On a worldwide basis, we employed 52,069 full-time employees (48,584 in Google and 3,485 in Motorola Mobile) as of June 30, 2014, compared to 49,829 full-time employees (46,170 in Google and 3,659 in Motorola Mobile) as of March 31, 2014."

GOOG closed on 02014.07.17 at $573.73. 52-week range: $502.80 - $604.83. GOOGL closed on 02014.07.17 at $580.82. 52-week range: $421.91 - $615.05.

I've been tracking Google's quarterly results since 4Q'08.

Thursday, July 17, 2014

Bought Some More StemCells (STEM) at $1.69

Bought some more StemCells (STEM) today (02014.07.17) at $1.69. The company is making progress, but it's costing the company a lot of money to make the progress.

Tuesday, July 15, 2014

Yahoo! (YHOO) Reports 2Q'14 (Yahoo! Unhappy With Revenues)

Yahoo! (YHOO) reported 2Q'14 results after the market closed today. CEO Marissa Mayer started the press release with the following sentence: "Our top priority is revenue growth and by that measure, we are not satisfied with our Q2 results."

Two items from the 2Q'14 press release.

"Cash, cash equivalents, and investments in marketable securities were $4.3 billion as of June 30, 2014 compared to $5 billion as of December 31, 2013, a decrease of $0.7 billion."

"During the second quarter of 2014, Yahoo repurchased approximately 21 million shares for $719 million."

I liked the following paragraph from the 2Q'14 press release.

"We are pleased to announce today that we have entered into an amendment to the share repurchase agreement with Alibaba, reducing the number of shares that Yahoo is required to sell at the IPO from 208 million shares to 140 million shares. In addition, we are aware that there has been much discussion around the allocation of the Alibaba IPO proceeds. We would like to take this opportunity to let our investors know that we are committed to return at least half of the after-tax IPO proceeds to shareholders, in line with our overarching commitment to maximizing shareholder value through prudent capital allocation."

YHOO closed today (02014.07.15) at $35.61. 52-week range: $26.73 - $41.72.

Monday, July 14, 2014

2Q'14 Results Are Coming

Some of the GDT::Portfolio companies are going to start reporting 2Q'14 results this week. Given current market conditions, this is a dangerous time for companies to not "exceed expectations." And for some stocks, this is a dangerous time for companies not to exceed the already exceeded expectations.

Thursday, July 10, 2014

Cray (CRAY) Awarded $174 Million Supercomputer Government Contract

It's been a crappy market ever since Americans stop celebrating our most recent birthday. The GDT::Portfolio is getting hit hard today (02014.07.10), but there has been one exception: CRAY. 30 minutes after the market opened today, Cray Inc. issued a press release titled: Cray Awarded $174 Million Supercomputer Contract From the National Nuclear Security Administration. CRAY closed yesterday (02014.07.09) at $27.22. CRAY spiked to $31.25 after the company posted its press release. Right now (10:05am EDT) CRAY is at $30.43. 52-week range: $20.87 - $42.09.

Tuesday, July 8, 2014

NeuroMetrix (NURO) Spikes Up

NeuroMetrix (NURO) closed yesterday (02014.07.07) at $1.89. Today it had a spike open at $2.84 and it continued up to $3.15 before falling to its current price of $2.64 at 10:04 EDT. Volume is already at 3.98 million vs. a full day average of 0.12 million. Prior to the market opening today (02014.07.08), the company issued a press release having the title: FDA Clears NeuroMetrix Wearable Technology for Over-the-Counter Use in Treatment of Chronic Pain.